4-(Pyridin-3-yl)-1H-pyrazol-1-yl-phenyl-3-benzamide　derivatives　have　been　proposed　as　new　BCR-ABL　tyrosine　kinase　inhibitors　by　using　combinational　strategies　of　scaffold　hopping　and　conformational　constraint.　In　the　present　study,　a　series　of　4-(pyridin-3-yl)-1H-pyrazol-1-yl-phenyl-3-benzamide　derivatives　were　synthesized　and　their　activities　against　BCR-ABL1　kinase　in　vitro　were　evaluated　by　using　Kinase-Glo　assay.　All　new　compounds　showed　from　moderate　to　potent　activities　against　wild-type　(wt)　BCR-ABL1　kinase　with　an　IC50　range　from　14.2　to　326.0　nM.　Among　them,　seven　compounds　exhibited　BCR-ABL1　kinase　inhibitory　activities　with　IC50　values　less　than　50　nM.　Compound　7a　displayed　the　most　potent　inhibitory　activity　to　BCR-ABL　kinase　(IC50:　14.2　nM).　Docking　simulation　was　performed　for　compounds　7a　and　7i　into　the　BCR-ABL　kinase　structure　active　site　to　determine　the　probable　binding　model.　The　preliminary　structure-activity　relationship　was　discussed.　The　interesting　activities　of　these　compounds　may　make　them　promising　candidates　as　therapeutic　agents　for　chronic　myelogenous　leukemia.　(C)　2015　Elsevier　Ltd.　All　rights　reserved.